Literature DB >> 2137212

Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7).

M Noguchi1, K Tajiri, T Taniya, T Kumaki, A Ashikari, I Miyazaki.   

Abstract

The influence of endocrine therapy on the proliferation of estrogen receptor (ER)-positive cells and ER-negative cells of human breast cancer (MFC-7) serially transplanted into nude mice was analyzed by tumor growth, dextran-coated charcoal (DCC) method, ER-immunocytochemical assay (ER-ICA) and ER-immunocytochemically stained 3H-thymidine autoradiography. In the tamoxifen (TAM) group and the medroxyprogesterone acetate (MPA) group, tumor growth was inhibited, but it was promoted in the 17-beta-estradiol dipropionate (E2) group. The ER level by the DCC method was significantly decreased in the TMA, the MPA and the E2 groups. The ER-ICA showed that the percentage of ER-positive cells was decreased in the TAM and the MPA group, but it was increased in E2 group. However, the ER-immunocytochemically stained 3H-thymidine autoradiography showed that not only the labelling index of ER-positive cells but also that of ER-negative cells was significantly decreased in the TAM and the MPA groups, while the labelling index was significantly increased in the E2 groups. Therefore, it was concluded that endocrine therapy affected the proliferation of both ER-positive cells and ER-negative cells of ER-positive breast cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137212     DOI: 10.1159/000226779

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  2 in total

1.  Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.

Authors:  K Szepeshazi; A V Schally; G Halmos; B Szoke; K Groot; A Nagy
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.

Authors:  I Soubeyran; N Quénel; L Mauriac; M Durand; F Bonichon
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.